Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2017

View Archived Issues

ICEC-0942 reduces tumor growth in preclinical models of breast cancer

Researchers develop a novel Crbn-mutant multiple myeloma mouse model

MAP1B gene found to be associated with periventricular nodular heterotopia

Phase II data presented for mAb hu3S193 in breast cancer patients

First patient treated in phase I study of Achillion's ACH-5228

European Commission approves Alecensa as first-line treatment in ALK-positive NSCLC

Frequency Therapeutics completes first-in-human study of drug candidate for hearing loss

Denali Therapeutics gives update on LRRK2 inhibitor programs

Arvinas selects second drug candidate

Jazz Pharmaceuticals submits NDA in U.S. for solriamfetol

First healthy subjects dosed in phase I trial of PRS-060

FDA issues complete response letter for Santen's NDA for intravitreal sirolimus

Spanish researchers patent RyR1 modulators

Novo Nordisk divulges new GDF-15 compounds

University of Patras presents geminin and Cdt1 interaction inhibitors

FDA grants priority review to Janssen's apalutamide NDA

An2H Discovery patents parkin modulators

Biohaven begins enrolling patients in phase II/III study of trigriluzole

Millendo Therapeutics acquires Alize Pharma

FDA approves ertugliflozin and combination therapies for type 2 diabetes

BAN-2401 does not meet criteria for success in phase II Alzheimer's study

BioLineRx begins phase III GENESIS trial

Ironwood Pharmaceuticals begins phase II study of IW-1701 in sickle cell disease

Celgene updates findings from phase III study of Revlimid plus rituximab in follicular lymphoma

Avelumab in combination with axitinib awarded FDA breakthrough therapy designation

FDA approves Giapreza to increase blood pressure in patients with septic or other distributive shock

Ionis Pharmaceuticals commences phase I trial of orally delivered antisense drug

FDA gives RMAT designation to Mesoblast's MPC therapy in heart failure

Roche to acquire Ignyta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...